These pot stocks are bad news for investors.
News & Analysis: Axim Biotechnologies
Whether it's a single-drug portfolio or little cash on hand, these drug developers are the definition of risk.
These cannabinoid-based drug developers have recently gone up in smoke.
Despite big gains, these pot stocks appear to be headed in diverging directions.
Despite its big gains, this pot stock remains a going concern.
Pot stocks' average return exceeds 23 times the S&P 500's performance over the past year. But is it sustainable?
Axim Biotechnologies was the hottest marijuana stock of 2016, but it's cooled down considerably so far this year. Here's what you need to know about this former highflier.
There were 20,101 opioid-related overdose deaths in 2015, compared to zero overdose-related deaths for marijuana that year.
Does this expansive cannabinoid-based drug pipeline have what it takes to put "green" in investors' pockets?
Analyst notes were a big catalyst for pot stocks last week.